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Abstract
Introduction: Effective diagnosis of cardiovascular diseases requires the right tools to be used enabling selective and sensitive analysis of their bi-
omarkers. One of them is homocysteine (Hcy), nowadays determined by immunoassays and chromatographic methods. This study aims to compare 
the results obtained by direct chemiluminescence immunoassay (CLIA) and high performance liquid chromatography with fluorescent detection 
(HPLC-FD) using commercial kits. 
Materials and methods: Homocysteine concentration was determined in serum samples obtained from 101 individuals, using Atellica IM HCY 
(Siemens Healthineers, Erlangen, Germany) and HCY in plasma/serum – HPLC-FD (Chromsystems Instruments & Chemicals GmbH, Gräfelfing, Ger-
many) tests validated for routine analysis. The latter was applied as a reference method. The comparability and agreement between the tested met-
hods were evaluated using the Passing-Bablok (PB) regression analysis and the Bland-Altman (BA) method of the differences analysis.
Results: Studies showed that CLIA gives higher Hcy concentrations (15.7 ± 4.14 μmol/L). Passing-Bablok regression analysis of the results obtained 
with CLIA (y) compared with HPLC-FD (x) yielded an intercept of 0.22 (95%CI: - 2.16 to 2.46) and slope of 1.58 (95%CI: 1.33 to 1.87). Bland-Altman 
analysis demonstrated a systematic positive bias for CLIA of 5.85 ± 2.77 µmol/L.
Conclusions: Methods disagreement precludes their interchangeability. Lower Hcy values by HPLC-FD result from its greater selectivity. High per-
formance liquid chromatography with fluorescent detection should be considered as preferential method for analysing Hcy in blood serum as well as 
the recommended reference method for routine clinical analysis. This fact, however, imposes the need to establish new reference ranges.
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Introduction
Cardiovascular diseases (CVD) are one of the major 
health problems in the modern world. The WHO 
data reveals that unfortunately, CVD are the main 
cause of people mortality (1). Therefore in the lab-
oratory practice effective diagnostic tools are 
needed that allow for selective and sensitive anal-
ysis of cardiovascular diseases markers. 
Many clinical and epidemiological studies have 
confirmed the significant relationship between hy-
perhomocysteinemia, i.e. a medical condition char-
acterized by a high homocysteine in the blood and 
the risk of myocardial infarction in general popula-
tion (2-5). Therefore homocysteine (Hcy), the sul-
phur amino acid formed during metabolism of me-
thionine may be considered as a biomarker and its 
high level as a prognostic factor for cardiovascular 
events and mortality (6-8). It is worth noting that 
CVD patients with high total homocysteine (tHcy) 
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concentrations (above 13-15 μmol/L) belong al-
ready to a high-risk group (especially with coronary 
artery disease, diabetes and renal failure) (5,6). There 
can be many causes of hyperhomocysteinemia. 
Some of them are nutritional deficiencies of folate, 
vitamins B6 and B12, and genetic defects of enzymes 
(particularly methylenetetrahydrofolate reductase 
(MTHFR) and cystathionine-β-synthase (CBS)) in-
volved in Hcy metabolism (3). Scientific and clinical 
research confirmed also higher Hcy concentrations 
in the serum of patients with Alzheimer’s disease, 
Parkinson’s disease, type 2 diabetes, metabolic syn-
drome, cancers and psychiatric disorders. High Hcy 
concentrations are also related to pregnancy com-
plications and birth defects (4,5). In view of the 
above, the determination of tHcy in serum is an im-
portant diagnostic test requiring appropriately sen-
sitive, but also specific analytical methods.
Homocysteine determination can be performed 
by many analytical techniques. The routinely used 
diagnostic methods are immunoassays, such as 
enzyme immunoassay (EIA), fluorescence polariza-
tion immunoassay (FPIA) and chemiluminescence 
immunoassay (CLIA) (6,9). However, recently the 
interest in the use of chromatographic methods in 
the diagnostic tests has increased (10). There are 
many chromatographic techniques. Yet of all, liq-
uid chromatography methods coupled to various 
selective detectors such as a fluorescence detector 
(FD) or a mass spectrometric detector are most 
frequently applied. These methods combine the 
separation power of chromatographic columns 
and the specific identity of detection techniques 
so they are regarded as the gold analytical stand-
ard suitable for very sensitive and selective analy-
sis of organic compounds in the complex biologi-
cal matrices. Compared to the immunological 
methods, they are distinguished not only by high 
specificity but also the ability to analyse various 
compounds at very different concentration levels 
as well as in a wide concentration range, often 
during the same analysis (9,11,12). For these rea-
sons, chromatographic methods are becoming in-
creasingly popular and even recommended as ref-
erence methods in routine clinical analysis (10-13). 
In the literature, one can find the data assessing 
the compatibility of the homocysteine determina-
tions by immunological methods, mainly FPIA and 
EIA, with the chromatographic ones (6,14-18). Ac-
cording to the authors’ knowledge, however, there 
is no data on the assessment of the obtained re-
sults in terms of compliance of the direct chemilu-
minescence immunoassay method to the chroma-
tographic method validated to the routine analy-
sis. Therefore the aim of this study was to compare 
the compatibility of the homocysteine determina-
tions by the CLIA method, routinely used in our 
laboratory, with the ready to use high perfor-
mance liquid chromatography with fluorescent 
detection (HPLC-FD) method. 
Materials and methods
Subjects
The serum samples used in the study (N = 101; 11 
men and 90 women) were randomly selected from 
blood samples obtained from patients who un-
derwent medical assessment of Hcy concentration 
during our laboratory standard practices (Alab 
Laboratories, Lublin, Poland). Blood was collected, 
in accordance with local and national regulations 
on ethics, from the patients only during their labo-
ratory tests - no additional material was collected 
from the patients more than required for the med-
ical evaluation of Hcy concentration.
The blood samples were obtained by fasting vein 
puncture, in the morning from 7.30 to 11 am. The 
blood was collected into the Sarstedt Monovette 
Homocysteine Z-Gel tubes containing a homo-
cysteine stabilizer (SARSTEDT AG & Co. Nümbre-
cht, Germany), that provides stability for up to 96 
hours if stored at room temperature, up to 1 
month if refrigerated, and up to 10 months if fro-
zen.  The tubes have been tested to validate their 
suitability for the CLIA and HPLC-FD methods by 
the manufacturer (19). The serum was separated 
within 45 minutes of blood collection by centrifu-
gation (2500 rpm; 5 min at room temperature) and 
frozen at - 20°C until testing. The samples were 
stored for up to three days prior to analysis.
Methods
The tests were carried out using the standard diag-
nostic analysers Atellica IM 1600 (Siemens Health-
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ineers, Erlangen, Germany) and the HPLC-FD system 
(NexeraX2, Shimadzu Corporation, Kyoto, Japan) 
under conditions indicated by the kit manufactures. 
The assays were carried out simultaneously by both 
methods to avoid any possible changes in Hcy and 
according to the instructions supplied by the manu-
factures of the respective kits. 
The Atellica IM HCY test is a competitive immuno-
assay using direct chemiluminescence based on a 
three-step procedure. Firstly, a reducing reagent 
(dithiothreitol) is used to release Hcy bound to the 
plasma proteins. Then the total homocysteine, i.e. 
the sum of free Hcy as well as that released, is con-
verted to S-adenosylhomocysteine (SAH) using an 
enzyme reagent (S-adenosylhomocysteine hydro-
lase). In a patient sample SAH competes with SAH 
covalently bound to the paramagnetic particles in 
a solid phase reagent, for a limited number of 
binding sites with the mouse monoclonal antibod-
ies (anti-SAH) labelled with the acridine ester used 
as a chemiluminescent tracer. The amount of Hcy 
was calculated by relating the SAH chemilumines-
cence response to the SAH calibration curve ob-
tained using the highly purified SAH calibrators 
(LOT no. 36852) supplied by the kit manufacture. 
Control materials from the kit manufacturer were 
used to carry out quality control (lot 36853).
The used HPLC-FD method is a multi-step proce-
dure intended for the routine Hcy determination 
using a selective separation column as well as a se-
lective fluorescence detector operating at two 
wavelengths (385 nm for excitation and 515 nm for 
emission). As in the previous method, the first 
stage involves reducing the plasma protein bound 
Hcy (using a reduction reagent - lot 4618) to a free 
form so that the total homocysteine can be deter-
mined. The next step, that distinguish this method 
from the previous one, is the precipitation of se-
rum proteins using a precipitation reagent (lot 
4618). The purified sample is subjected derivatiza-
tion using a derivatizing reagent (lot 4618), fol-
lowed by the HPLC-FD analysis. During the chro-
matographic analysis, the individual sample com-
ponents are separated based on the differences in 
the affinity for the stationary phase (HPLC – col-
umn, order no. 39100) and the mobile phase (lot 
2719) (both supplied by the kit manufacturer), 
which causes them to migrate at different rates to 
a detector where they are selectively and sensi-
tively detected. The amount of Hcy was calculated 
by relating the Hcy chromatographic response to 
the Hcy calibration curve obtained using the high-
ly purified Hcy calibrators (lot 0818) and the inter-
nal standard (lot 04618), both supplied by the kit 
manufacture. To check the correctness of the cali-
bration, control tests at two homocysteine levels 
(Plasma Control Level I and Plasma Control Level II, 
lot 0919) were analysed. The correctness of the cal-
ibration was confirmed by obtaining results within 
the manufacturer’s declared range of homocyst-
eine concentrations in the control samples.
Statistical analysis
Method comparison was performed using the 
Passing-Bablok regression analysis and the Bland-
Altman method for the differences analysis with 
an agreement indicator (bias between methods), 
recommended by the Clinical and Laboratory 
Standard Institute (CLSI) (20-23). 
The Passing-Bablok regression analysis of the re-
sults is presented with a scatter diagram, a regres-
sion line, as well as a regression equation, where 
the intercept and slope represent respectively a 
constant difference interpreted as the systematic 
bias and the proportional measurement error be-
tween the methods. 95% confidence interval (CI) 
of the intercept and the slope explains if their val-
ue differ from value zero (intercept) and value one 
(slope). If 0 is in the CI of the intercept, and 1 is in 
the CI of the slope, the two methods are compara-
ble within the investigated concentration range. 
The Bland-Altman analysis of differences describes 
agreement between two quantitative methods by 
constructing limits of agreement. These limits are 
calculated by the mean and standard deviation 
(SD) of the differences between two measure-
ments. If the differences are normally distributed 
the limits of agreement = the mean ± 1.96 SD (95% 
of differences is located between the mean - 1.96 
SD and the mean + 1.96 SD). The mean difference 
is interpreted as the systematic bias.
The D’Agostino-Pearson test was used to check 
the normality of the differences between the test-
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ed methods. P < 0.05 was considered significant. 
The statistical analysis was carried out using the 
MedCalc Statistical Software Version 19.1.3 (Os-
tend, Belgium) and GraphPad Prism 8.30 (Graph-
Pad Software, San Diego, USA).
Results
Descriptive statistics of Hcy results obtained by 
the CLIA and HPLC-FD methods is presented in Ta-
ble 1. Distribution plots of differences between 
Hcy measurements by CLIA and HPLC-FD methods 
and Q-Q plots are presented in Figure 1. The Pass-
ing-Bablok regression analysis of the results ob-
tained with CLIA (y) compared with HPLC-FD (x) is 
presented in Figure 2. The comparison of the 
methods yielded the following equation: y = 0.22 
+ 1.58 x. 95% CI for the intercept is from - 2.16 to 
2.46 and for the slop from 1.33 to 1.87. These re-
sults indicated proportional difference between 
methods. 
The Bland-Altman difference plots are shown in 
Figure 3, and the results of statistical analysis in Ta-
ble 2. It was found that the CLIA results for the 
whole tested range of Hcy concentrations were 
higher than the HPLC results. Graphical presenta-
tion of the tHcy measurements performed with 
the HPLC and CLIA methods is presented in Figure 
Hcy concentrations (N = 101)
CLIA HPLC-FD
Mean ± SD 15.70 ± 4.14 9.86 ± 3.02
Minimum 9.10 4.63
Maximum 28.83 25.46
CLIA – direct chemiluminescence immunoassay. HPLC-FD – 
high performance liquid chromatography with fluorescent 
detection. Hcy – homocysteine. SD - standard deviation.





95% CI of the mean 5.298 to 6.394
95% Lower LoA 0.408
95% Upper LoA 11.284
CLIA – direct chemiluminescence immunoassay.  HPLC-FD – 
high performance liquid chromatography with fluorescent 
detection. Hcy – homocysteine. CI – confidence interval. LoA 
– limit of agreement.
Table 1. Descriptive statistics of homocysteine results obtained 
by the CLIA and HPLC-FD methods
Figure 1. Distribution plots of differences between Hcy measurements by CLIA and HPLC-FD methods and Q-Q plots. CLIA - direct 
chemiluminiscence immunoassay. HPLC-FD - high-performance liquid chromatography with fluorescent detection.
Table 2. Bland-Altman statistical analysis of differences be-
tween serum tHcy concentrations measured by the CLIA com-
pared with HPLC-FD methods
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Discussion 
This study compares the two analytical methods 
used in the laboratory practice, direct chemilumi-
nescence immunoassay and high performance liq-
uid chromatography with fluorescent detection, 
to determine the concentration of total homocyst-
eine in the blood serum. HPLC-FD was chosen as 
the reference method. The obtained results 
showed that the tHcy concentrations measured by 
the CLIA method are higher than those obtained 
by HPLC-FD. 
Chromatographic methods and especially those 
coupled with very specific and as a consequence 
very sensitive detectors, such as the fluorescence 
detector are widely recognized as very accurate 
and precise analytical tools. The HPLC-FD systems, 
due to the requirement of the derivatization of the 
analysed compound, in addition to the application 
of a separation column able to resolve a mixture of 
very similar compounds, guarantee a high level 
specificity of the determination. Moreover, the re-
quirement for proper sample preparation prior to 
the analysis further increases the selectivity level. 
In turn, the application of the internal standard en-
hances the precision of the quantitative analysis. 
The immunoassays routinely used in laboratory di-
agnostics are sensitive and precise enough, but 
unfortunately their specificity is often lower com-
Figure 2. Passing-Bablok regression analysis of the results ob-
tained with the direct chemiluminescence immunoassay (CLIA) 
compared with high-performance liquid chromatography with 
fluorescent detection (HPLC-FD). The dashed lines represent 
the 95 % confidence intervals for the regression line. The iden-
tity line is represented as dotted.
Figure 3. The Bland-Altman plots showing the difference in 
the Hcy results (µmol/L) between the two methods (CLIA and 
HPLC-FD), as a function of their mean value. Grey lines present 
confidence interval limits for mean and agreement limits. CLIA 
- chemiluminiscence immunassay. HPLC-FC - high-performance 
liquid chromatography with fluorescent detection.
Figure 4. Graphical presentation of the Hcy measurements 
performed with the direct chemiluminescence immunoassay 
(CLIA) and high-performance liquid chromatography with fluo-
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4. The mean difference for CLIA vs HPLC-FD was 
5.85 µmol/L (systematic positive bias) with a stand-
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pared to the chromatographic methods. The low-
er specificity of the CLIA method may therefore 
explain the observed higher homocysteine con-
centrations obtained by this method compared to 
the HPLC-FD method.
Comparative analysis performed to assess the 
agreement between the results obtained by the 
comparable methods indicated proportional dif-
ference and systematic positive bias. The system-
atic positive bias for CLIA suggests that the meth-
odological differences of both methods may be 
responsible for the discrepancy between the tHcy 
results in the same patients group. Similar conclu-
sions were drawn by the authors of other papers 
comparing immunoassays (e.g. ICL-Immulite 2000, 
Abbot IMx and Abbott AxSYM or Bio-Rad EIA im-
munoassays) with HPLC methods (23-25).
Demuth et al. for example, performed the evalua-
tion of the agreement between the ADVIA Cen-
taur and HPLC-FD methods (the latter was their in-
house method developed based on the method 
previously described by Fortin and Genest (26,27). 
Their studies showed a systematic positive bias of 
3.0 µmol/L for the ADVIA Centaur, which accord-
ing to the authors excludes the possibility of inter-
changeable use of the ADVIA Centaur and HPLC-FD 
methods. The reference ranges for Hcy concentra-
tion determined by both methods prove the cor-
rectness of this conclusion. These results show 
that the ADVIA Centaur method gave significantly 
higher Hcy values (mean: 12.6±3.3 with a central 
95% range of 8.0–20.3 µmol/L) than the HPLC 
method (mean 9.5±2.5 with a central 95% range of 
5.7–15.8 µmol/L) for the same patients samples 
(26). Referring the results obtained by us to those 
cited above, it can be stated that the systematic 
positive bias of 5.85 µmol/L for the CLIA method 
excludes the possibility of interchangeable use of 
the CLIA method with HPLC-FD.
The lack of specificity of the analytical method is 
most often the reason for the systematic bias. 
However, there are other possible reasons for the 
low agreement between the results obtained by 
the compared methods. Some of them are dis-
cussed below. 
In the past poor quality reagents and access to in-
appropriate reference materials were a problem 
causing systematic errors. However, in this study 
equipment, reagents as well as controls and cali-
brators were provided by the kit manufacturers 
with the declared certificates (declaration of con-
formity according to directive 98/79 EC on in vitro 
diagnostic medical devices - CE IVD mark). Anoth-
er one is that the Atellica IM HCY method, contrary 
to the HPLC-FD one, is fully automated. Hence, in 
the former the risk of error of the analyst perform-
ing the determination has therefore been signifi-
cantly reduced. The possible limitation of the 
HPLC-FD method may be the potential risk with 
destruction of the fluorescent tHcy adduct by light 
after derivatization that could be the reason for 
the lower tHcy concentrations observed applying 
the HPLC-FD method. However, the results pre-
sented by Ubbink et al. showing great consistence 
of the results obtained by the HPLC-FD and GC-MS 
methods (the mean difference between the meth-
ods was - 1.42 µmol/L resulting in the mean pro-
portional bias: - 6.2%) eliminated this possibility 
(17). In addition, to protect the samples against the 
light, the non-transparent dark vials were used 
provided by the kit manufacturer in which the 
samples were prepared for analysis to limit this 
potential source of error. 
In the light of the above, it should be stated that 
the lower homocysteine values obtained by HPLC-
FD compared to CLIA result from the greater selec-
tivity of the first method, which makes it a prefer-
ential method for analysing the total concentra-
tion of homocysteine in the patient’s blood serum. 
This fact, however, imposes the need to set new 
reference ranges.
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